Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2025-09-12 Delisting Announcement
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 11, 2025, by VYNE Therapeutics Inc. The key content is an Item 3.01 notice regarding non-compliance with Nasdaq's minimum bid price requirement and the potential for delisting if compliance is not regained. This is a regulatory announcement about the company's stock listing status, specifically a delisting notice or warning. The document does not contain financial statements or detailed financial analysis but is an official notice of a potential delisting event. Therefore, the appropriate classification is Delisting Announcement (DLST). The document length is 5437 characters, which is sufficient to contain the full notice rather than just a brief announcement or reference to another report.
2025-09-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes an Item 2.02 Results of Operations and Financial Condition, referencing a press release of quarterly financial results for the quarter ended June 30, 2025, but it does not contain the financial results itself, only a mention that the press release is furnished as an exhibit. It also includes Item 5.02 regarding resignation of directors, which is a management/board change announcement. The document is not a full quarterly or annual report but a current report announcing events and referencing a press release. The presence of director resignations points to management information. Since the document is a Form 8-K current report with multiple items including management changes and financial results announcement, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Confidence is high because the document is clearly a Form 8-K current report with multiple announcements and no full financial statements or detailed reports included.
2025-08-14 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes a press release and a presentation about topline results from a Phase 2b trial and preliminary financial information for the quarter ended June 30, 2025. The document does not contain full financial statements or detailed financial analysis but rather announces results and events. Form 8-K filings are regulatory filings used to report significant events and updates. Therefore, this document fits best under the category of Regulatory Filings (RNS).
2025-07-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.